Taconic Biosciences
78 articles about Taconic Biosciences
-
H.I.G. Capital Completes Sale of Taconic Biosciences
11/1/2022
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $52 billion of equity capital under management, is pleased to announce the sale of its portfolio company Taconic Biosciences (“Taconic” or the “Company”) to Avista Capital Partners (“Avista”).
-
Avista Capital Partners Acquires Taconic Biosciences
11/1/2022
Avista Capital Partners, a leading private equity firm focused exclusively on healthcare, announced its acquisition of Taconic Biosciences, a leading provider of genetically engineered research models and related services, from H.I.G. Capital.
-
Taconic Biosciences Launches First and Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors, for Improved Antibody Therapy Assessment
10/24/2022
Taconic Biosciences has launched the FcResolv™ NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors known to confound results in antibody-based therapy studies.
-
Taconic Biosciences Appoints Nomura Siam as Distributor in India for All Taconic Animal ModelsImproves Access to Critical Rodent Models for Researchers in India
5/10/2022
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd (NSI), an established distributor of laboratory animals and related products, as its preferred distributor in India.
-
Taconic Biosciences and Biomodels Establish Microbiome InitiativeSeamless, Comprehensive Capabilities Eliminate Barriers to Microbiome Research
4/26/2022
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data.
-
Taconic Biosciences Improves rasH2 Carcinogenicity Test System Access in Asia-Pacific RegionFour-way distribution partnership provides quality, consistent rasH2 supply to India and China, better serving global customers
3/21/2022
Taconic Biosciences has appointed Nomura Siam International Co., Ltd. (NSI) and Nomura Jimusho. Inc. (NJI) as sales agents and distributors of the rasH2 Mouse Carcinogenicity Test System in India and China, respectively.
-
Taconic Biosciences® Launches Cage+™, Redefining Colony Management Solutions for the Modern Laboratory
2/21/2022
aconic Biosciences delivers complete stewardship of projects from start to finish, allowing investigators to focus on research with confidence that animal model supply is reliable, at the highest quality, and on budget.
-
Taconic Biosciences Launches New COVID-19 Mouse ModelExpands COVID-19 Research Toolkit with novel hACE2 AC22 Mouse
4/29/2021
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model.
-
Taconic Biosciences Expands Scientific Advisory BoardDr. Monica Gostissa Joins Taconic Biosciences’ Scientific Advisory Board
3/15/2021
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces Monica Gostissa, PhD, has joined its Scientific Advisory Board (SAB). Dr. Gostissa joins existing board members, Frank Sistare, PhD; Andrew Goodman, PhD; David Hill, PhD; and Robert Rosenthal, PhD.
-
Taconic Biosciences Expands Immuno-oncology Animal Model PortfolioCritical Jh Syngeneic Tumor Model Host Now Available on a B6 Background
1/18/2021
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio.
-
Taconic Biosciences Expands Innovative ExpressMODEL® PortfolioNew Random Integration Transgenic Animal Model Generation Solution Available
12/3/2020
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the new ExpressMODEL ® : Random Integration Transgenic ( RITg ) service, which reduces animal model generation costs and timeline. Many gene editing technologies are used to generate animal models for drug discovery, each with unique considerations but with the shared goal of creating specific genetic profiles. The t
-
Taconic Biosciences launches critical model for COVID-19 researchImmediate availability of hACE2 mouse
10/26/2020
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces immediate humanized ACE2 mouse model availability for COVID-19 research.
-
Taconic Biosciences Expands Production of Critical Immunodeficient ModelLocal Production of the CIEA NOG mouse® Model Now Available on the West Coast
6/10/2020
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces local West Coast United States production of the immunodeficient CIEA NOG mouse ® model. Immunodeficient animal models are critical to the drug discovery ecosystem. One of the most common contributors to the high product attrition rate for this industry is difficulty recapitulating the human biosystem in an animal model. Immunodeficient mod
-
Taconic Biosciences Launches Rapid Restart™ ProgramFirst Animal Model Provider to Create Program Aiding Researchers Planning for Return
5/18/2020
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the successful implementation of its Rapid Restart™ program. Launched over a month ago, Taconic was the first animal model provider in the industry to provide researchers with a program specifically designed to aid laboratories transitioning back to increased productivity. COVID-19 forced many institutions to discontinue critical research prog
-
Taconic Biosciences Supports Coronavirus ResearchAnnounces Preclinical COVID-19 Research Tools
3/20/2020
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces support for global COVID-19 research efforts via a new Coronavirus Toolkit featuring relevant models and services. Mouse models have been extensively used for research on the SARS-CoV virus, closely related to the new SARS-CoV-2 virus that causes COVID-19. Taconic offers many animal models and services to support COVID-19 research and em
-
Taconic Biosciences Expands Humanized Mouse Model ProductionLocal Production of Critical Immuno-oncology Models Now Available in Europe
2/14/2020
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces its humanized immune system mice models are now being produced in Europe.
-
Taconic Biosciences Launches New Immuno-oncology Mouse ModelExpands and Broadens Taconic Biosciences’ Immuno-oncology Portfolio Application
1/31/2020
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model.
-
Taconic Biosciences Announces New San Diego LocationLocal Commercial Animal Model Production and Colony Management Services Available to West Coast Customers
1/2/2020
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the availability of both commercial animal model production and colony management services through a new location in San Diego.
-
Taconic Biosciences Launches Alzheimer’s Disease Mouse ModelProven Model Available Exclusively From Taconic Biosciences
11/4/2019
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its robust neurodegeneration portfolio with the launch of a new Alzheimer’s disease model, the ARTE10 mouse model.
-
Taconic Biosciences Announces New Scientific Advisory Board MemberDr. Frank Sistare Joins Taconic Biosciences’ Scientific Advisory Board
10/17/2019
Dr. Sistare joins existing SAB members Andrew Goodman, PhD, David Hill, PhD, and Robert Rosenthal, PhD.